Study record · Mazdutide
GLORY-2: 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
Phase 3 high-dose study demonstrated clinically meaningful weight reduction; full outcome-by-outcome extraction retained in source review queue.
Key result
Phase 3 high-dose study demonstrated clinically meaningful weight reduction; full outcome-by-outcome extraction retained in source review queue.
Study details
Study designRandomized, double-blind, placebo-controlled trial
PhasePhase 3
PopulationChinese adults with obesity, with or without type 2 diabetes
Sample size462
RouteSubcutaneous
Regimen / exposure9 mg once weekly
Duration60 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change and ≥5% weight loss
Safety resultTrial-level adverse-event profile must be read alongside full paper; GI effects remain class-consistent.
Key limitationsChinese population; 9 mg regimen differs from 4/6 mg GLORY-1; detailed subgroup extraction ongoing.
Registry / identifierGLORY-2